SPOTLIGHT -
In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.
Durect’s Larsucosterol Receives FDA Breakthrough Therapy Designation for Severe Alcohol-Associated Hepatitis
Moving forward, Durect plans on incorporating feedback from the FDA in the design of a Phase III trial.
FDA Approves Biocon Biologics’ Yesafili, an Eylea Biosimilar, for the Treatment of Multiple Ophthalmic Conditions
Approval of Yesafili represents Biocon’s entrance into the US ophthalmology market, following previous approvals in Europe and the UK.
FDA Grants Accelerated Approval to Amgen’s Imdelltra for the Treatment of Adults with Extensive-Stage Small Cell Lung Cancer
Imdelltra (tarlatamab-dlle) is the first T-cell engager therapy approved for extensive stage small cell lung cancer.
FDA Grants Accelerated Approval to Breyanzi for Relapsed or Refractory Follicular Lymphoma
This is the second accelerated approval the FDA has granted to Bristol Myers Squibb’s chimeric antigen receptor T-cell therapy in the past few months.
Non-Compete Clauses and the Nursing Shortage: Q&A with Matt Hollingsworth
Carta Healthcare’s co-founder discusses how a recent ruling on non-compete clauses may help alleviate the coming nursing shortage.
FDA Approves Roche’s HPV Self-Collection Solution, Allowing Patients to Gather Their Own Samples in a Healthcare Setting
Roche’s human papillomavirus solution is reportedly one of the first of its kind to be available in the United States.